![](/wp-content/uploads/2019/12/arecor-announcement.png)
$599
Arecor uRAI (AT247) Positive Topline Results
Arecor announced positive topline results for a Ph1 study of its ultra-rapid-acting insulin (AT247). Arecor did not provide any specifics of the Ph1 data, but the company plans to publish and present results from the study in 2020. Below, FENIX provides brief thoughts on AT247 and its market potential.